Update publication information. Antipsychotic (AP) drugs are common agents for treating mental disorders such as schizophrenia, bipolar disorder, and major depressive disorder. Overall AP prescription increased 3.8-fold, while second-generation AP (SGA) prescriptions increased 18.1-fold during a 16-year follow-up. The increased use of APs has led to public concern on the cardiac adverse effect, termed as cardiotoxicity, which is an uncommon but deadly effect, in addition to metabolic abnormalities. It has been estimated that long-term use of first-generation AP (FGA) and SGA drugs showed higher rates of sudden cardiac death than did nonusers of AP drugs, with adjusted incidence-rate ratios of 1.99 and 2.26, respectively. Despite extensive clinical concern on the AP drug safety, the rescue strategy has remained largely unchanged for years. When situated for AP drugs-induced dysrhythmia, administrative offices or clinicians usually withdraw or discontinue the offending drugs, a passive action that unfortunately leads to economic waste of on-the-market drugs. Therefore, in-depth investigation of APs cardiotoxicity with systemic evidence remains urgently needed.